收费全文 | 47198篇 |
免费 | 2296篇 |
国内免费 | 168篇 |
耳鼻咽喉 | 1036篇 |
儿科学 | 2203篇 |
妇产科学 | 1402篇 |
基础医学 | 5105篇 |
口腔科学 | 1826篇 |
临床医学 | 3845篇 |
内科学 | 8353篇 |
皮肤病学 | 1072篇 |
神经病学 | 3833篇 |
特种医学 | 1696篇 |
外国民族医学 | 2篇 |
外科学 | 8636篇 |
综合类 | 355篇 |
现状与发展 | 1篇 |
一般理论 | 15篇 |
预防医学 | 3733篇 |
眼科学 | 1154篇 |
药学 | 3009篇 |
中国医学 | 225篇 |
肿瘤学 | 2161篇 |
2023年 | 432篇 |
2022年 | 384篇 |
2021年 | 905篇 |
2020年 | 641篇 |
2019年 | 816篇 |
2018年 | 1391篇 |
2017年 | 1124篇 |
2016年 | 1334篇 |
2015年 | 1270篇 |
2014年 | 1625篇 |
2013年 | 2275篇 |
2012年 | 2886篇 |
2011年 | 3259篇 |
2010年 | 1796篇 |
2009年 | 1229篇 |
2008年 | 2142篇 |
2007年 | 2529篇 |
2006年 | 2303篇 |
2005年 | 2518篇 |
2004年 | 2284篇 |
2003年 | 2161篇 |
2002年 | 2013篇 |
2001年 | 1218篇 |
2000年 | 1308篇 |
1999年 | 1023篇 |
1998年 | 359篇 |
1997年 | 281篇 |
1996年 | 231篇 |
1995年 | 194篇 |
1992年 | 464篇 |
1991年 | 423篇 |
1990年 | 437篇 |
1989年 | 396篇 |
1988年 | 374篇 |
1987年 | 358篇 |
1986年 | 384篇 |
1985年 | 365篇 |
1984年 | 276篇 |
1983年 | 239篇 |
1979年 | 277篇 |
1978年 | 185篇 |
1975年 | 174篇 |
1974年 | 232篇 |
1973年 | 221篇 |
1972年 | 226篇 |
1971年 | 197篇 |
1970年 | 177篇 |
1969年 | 211篇 |
1968年 | 182篇 |
1967年 | 172篇 |
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献Aims
To examine the influence of pre-existing psychiatric disorder on the choice of treatment in patients with gynaecological cancer.Materials and methods
The analyses were based on all patients who underwent surgical treatment for endometrial, ovarian or cervical cancer who were registered in the Danish Gynecological Cancer Database in the years 2007–2014 (3059 patients with ovarian cancer, 5100 patients with endometrial cancer and 1150 with cervical cancer). Logistic regression model and Cox regression model, adjusted for relevant confounders, were used to estimate the effect of pre-existing psychiatric disorder on the course of cancer treatment. Our outcomes were (i) presurgical oncological treatment, (ii) macroradical surgery for patients with ovarian cancer, (iii) radiation/chemotherapy within 30 days and 100 days after surgery and (iv) time from surgery to first oncological treatment.Results
In the group of patients with ovarian cancer, more patients with a psychiatric disorder received macroradical surgery versus patients without a psychiatric disorder, corresponding to an adjusted odds ratio of 1.24 (95% confidence interval 0.62–2.41) and the chance for having oncological treatment within 100 days was odds ratio = 1.26 (95% confidence interval 0.77–2.10). As for patients with endometrial cancer, all outcome estimates were close to unity. The adjusted odds ratio for oncological treatment within 30 days after surgery in patients with cervical cancer with a history of psychiatric disorder was 0.20 (95% confidence interval 0.03–1.54).Conclusions
We did not find any significant differences in the treatment of ovarian and endometrial cancer in patients with pre-existing psychiatric diagnoses. When it comes to oncological treatment, we suggest that increased attention should be paid to patients with cervical cancer having a pre-existing psychiatric diagnosis. 相似文献Butyrylcholinesterase (BChE) is a serine esterase that plays a role in the detoxification of natural as well as synthetic ester-bond-containing compounds. Alterations in BChE activity are associated with a number of diseases. Cholinergic system abnormalities in particular are correlated with the formation of senile plaques in Alzheimer’s disease (AD), and administration of cholinesterase inhibitors is a common therapeutic approach used to treat AD.
Here, our aim was to study the interaction between BChE and fluoxetine.
Molecular docking simulations revealed that fluoxetine penetrated deep into the active-site gorge of BChE and that it was engaged in stabilizing noncovalent interactions with multiple subsites. In substrate kinetic studies, the Vm, Km, kcat and kcat/Km values were found to be 20.59?±?0.36?U mg?1 protein, 194?±?14?µM, 1.3?×?108?s?1 and 6.7?×?105?µM?1s?1, respectively. Based on inhibitory studies, fluoxetine appeared to inhibit BChE competitively, with an IC50 value of 104?µM and a Ki value of 36.3?±?4.7?µM.
Overall, both the low Ki value and the high number of BChE–fluoxetine interactions suggest that fluoxetine is a potent inhibitor of BChE, although in vivo mechanisms for the direct effects of BChE inhibition on various pathologies remain to be further investigated.